Photochemotherapy for severe psoriasis without or in combination with acitretin: A randomized, double-blind comparison study

https://doi.org/10.1016/0190-9622(91)70253-XGet rights and content

In a randomized, double-blind comparative study 60 patients with severe, widespread psoriasis were treated either with photochemotherapy (PUVA) alone or in combination with acitretin. Forty-eight patients completed the study; of these, 25 received placebo combined with PUVA and 23 received acitretin with PUVA. Marked or complete clearing of psoriasis occurred in 80% of the patients (20 of 25) without acitretin and in 96% of the patients (22 of 23) with adjunctive acitretin administration. The mean cumulative UVA dose given to patients in the acitretin-PUVA group was 42% less than that required for patients in the placebo-PUVA group. We conclude that acitretin substantially augments the efficacy of photochemotherapy in the treatment of severe psoriasis.

References (19)

There are more references available in the full text version of this article.

Cited by (160)

  • Role of phototherapy in the era of biologics

    2021, Journal of the American Academy of Dermatology
  • Systemic Retinoids

    2020, Comprehensive Dermatologic Drug Therapy, Fourth Edition
  • Psoralen-Ultraviolet Light A Therapy

    2016, Therapy for Severe Psoriasis
View all citing articles on Scopus

Supported by a grant from F. Hoffmann-La Roche & Co. Ltd.

View full text